Evidence map›Paper›PMID 35178052›Full record

ArticleFrontiers in immunology2022

Pharmacological Inhibition of FAK-Pyk2 Pathway Protects Against Organ Damage and Prolongs the Survival of Septic Mice.

Gustavo Ferreira Alves, Eleonora Aimaretti, Giacomo Einaudi, Raffaella Mastrocola, Junior Garcia de Oliveira, Debora Collotta, Elisa Porchietto, Manuela Aragno, Carlo Cifani, Regina Sordi and 3 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Pyk2 regulates sepsis-induced lung injury via ferroptosis.Iranian journal of basic medical sciences · 2023
    Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 3 countries.

Gustavo Ferreira AlvesDepartment of Neurosciences (Rita Levi Montalcini), University of Turin, Turin, Italy.
Eleonora AimarettiDepartment of Clinical and Biological Sciences, University of Turin, Turin, Italy.
Giacomo EinaudiPharmacology Unit, School of Pharmacy, University of Camerino, Camerino, Italy.
Raffaella MastrocolaDepartment of Clinical and Biological Sciences, University of Turin, Turin, Italy.
Junior Garcia de OliveiraDepartment of Pharmacology, Federal University of Santa Catarina, Florianópolis, Brazil.
Debora CollottaDepartment of Neurosciences (Rita Levi Montalcini), University of Turin, Turin, Italy.
Elisa PorchiettoPharmacology Unit, School of Pharmacy, University of Camerino, Camerino, Italy.
Manuela AragnoDepartment of Clinical and Biological Sciences, University of Turin, Turin, Italy.
Carlo CifaniPharmacology Unit, School of Pharmacy, University of Camerino, Camerino, Italy.
Regina SordiDepartment of Pharmacology, Federal University of Santa Catarina, Florianópolis, Brazil.
Christoph ThiemermannWilliam Harvey Research Institute, Bart's and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom.
Daniel FernandesDepartment of Pharmacology, Federal University of Santa Catarina, Florianópolis, Brazil.
Massimo CollinoDepartment of Neurosciences (Rita Levi Montalcini), University of Turin, Turin, Italy.
University of Turin · ITUniversidade Federal de Santa Catarina · BRUniversità di Camerino · ITQueen Mary University of London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sepsis and septic shock are associated with high mortality and are considered one of the major public health concerns. The onset of sepsis is known as a hyper-inflammatory state that contributes to organ failure and mortality. Recent findings suggest a potential role of two non-receptor protein tyrosine kinases, namely Focal adhesion kinase (FAK) and Proline-rich tyrosine kinase 2 (Pyk2), in the inflammation associated with endometriosis, cancer, atherosclerosis and asthma. Here we investigate the role of FAK-Pyk2 in the pathogenesis of sepsis and the potential beneficial effects of the pharmacological modulation of this pathway by administering the potent reversible dual inhibitor of FAK and Pyk2, PF562271 (PF271) in a murine model of cecal ligation and puncture (CLP)-induced sepsis. Five-month-old male C57BL/6 mice underwent CLP or Sham surgery and one hour after the surgical procedure, mice were randomly assigned to receive PF271 (25 mg/kg, s.c.) or vehicle. Twenty-four hours after surgery, organs and plasma were collected for analyses. In another group of mice, survival rate was assessed every 12 h over the subsequent 5 days. Experimental sepsis led to a systemic cytokine storm resulting in the formation of excessive amounts of both pro-inflammatory cytokines (TNF-α, IL-1β, IL-17 and IL-6) and the anti-inflammatory cytokine IL-10. The systemic inflammatory response was accompanied by high plasma levels of ALT, AST (liver injury), creatinine, (renal dysfunction) and lactate, as well as a high, clinical severity score. All parameters were attenuated following PF271 administration. Experimental sepsis induced an overactivation of FAK and Pyk2 in liver and kidney, which was associated to p38 MAPK activation, leading to increased expression/activation of several pro-inflammatory markers, including the NLRP3 inflammasome complex, the adhesion molecules ICAM-1, VCAM-1 and E-selectin and the enzyme NOS-2 and myeloperoxidase. Treatment with PF271 inhibited FAK-Pyk2 activation, thus blunting the inflammatory abnormalities orchestrated by sepsis. Finally, PF271 significantly prolonged the survival of mice subjected to CLP-sepsis. Taken together, our data show for the first time that the FAK-Pyk2 pathway contributes to sepsis-induced inflammation and organ injury/dysfunction and that the pharmacological modulation of this pathway may represents a new strategy for the treatment of sepsis.

Indexed as

AnimalsCytokinesDisease Models, AnimalFocal Adhesion Kinase 1Focal Adhesion Kinase 2InflammationLigationMaleMiceMice, Inbred C57BLMitogen-Activated Protein KinasesMultiple Organ FailureProtein Kinase InhibitorsRandom AllocationSepsisSurvival RateCytokinesFocal Adhesion Kinase 1Focal Adhesion Kinase 2Mitogen-Activated Protein KinasesProtein Kinase InhibitorsFocal adhesion kinase (FAK)inflammationNLRP3 inflammasomeproline-rich tyrosine kinase 2 (PYK2)sepsis

Identifiers

PMID35178052
PMCPMC8843946
OpenAlexW4210372845

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.